Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (9442)	3/30/1999 9:57:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Bluegreen, please stick to the issues. Robert K made a great find. Patients are being accrued. I doubt anyone can start this process if P III has not been approved by the FDA. So, it is obvious, a trial is underway. We do not know it is P III. It could be another P II trial. We do not know who is running the trial. Yes the drug is now called xoma/hu11124. I do not remember it being called anything but hu1124 before. While an indication it is not proof. Robert and others do not seem to understand why one would and in fact should be upset if shareholders were not told about XOMA's involvement.